Company Description
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer.
The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy.
It is also developing GC4711, a dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer.
The company was incorporated in 2012 and is based in Malvern, Pennsylvania.
| Country | United States |
| Founded | 2012 |
| IPO Date | Nov 7, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Dr. J. Mel Sorensen M.D. |
Contact Details
Address: 45 Liberty Blvd., Suite 230 Malvern, Pennsylvania 19355 United States | |
| Phone | 610-725-1500 |
| Website | galeratx.com |
Stock Details
| Ticker Symbol | GRTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $12.00 |
| CIK Code | 0001563577 |
| CUSIP Number | 36338D108 |
| ISIN Number | US36338D1081 |
| Employer ID | 46-1454898 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. J. Mel Sorensen M.D. | Chief Executive Officer, President and Director |
| Dr. Robert A. Beardsley M.B.A., Ph.D. | Co-Founder and Chief Operating Officer |
| Christopher Degnan | Chief Financial Officer |
| Jennifer Evans Stacey Esq. | Chief Legal and Compliance Officer and Secretary |
| Andie Collier | Chief Regulatory and Quality Affairs Officer |
| Judy Schnyder | Senior Vice President of Clinical Operations and Data Management |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Apr 3, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Mar 28, 2024 | 10-K | Annual Report |
| Mar 28, 2024 | 8-K | Current Report |
| Mar 27, 2024 | 8-K | Current Report |
| Feb 20, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 17, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jan 2, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Dec 4, 2023 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |